ETVAX®
Diarrhea caused by Enterotoxigenic Escherichia coli (ETEC) in travelers and endemic populations
Phase 2Active
Key Facts
Indication
Diarrhea caused by Enterotoxigenic Escherichia coli (ETEC) in travelers and endemic populations
Phase
Phase 2
Status
Active
About Scandinavian Biopharma Holding
Scandinavian Biopharma is a private, clinical-stage biopharma company specializing in vaccine development and distribution. Its lead asset, ETVAX®, is an oral vaccine candidate for ETEC diarrhea, which has completed a successful Phase 2b trial and is positioned for Phase 3. The company operates with a hybrid model, advancing its proprietary pipeline while also distributing specialty biopharma products, placing it in the 'Early Revenue' stage as it progresses its flagship program toward pivotal studies.
View full company profile